“The current scenario has exposed some structural weaknesses from the EU’s medicines supply chain plus a higher dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides reported. She encouraged that offer chain issues be resolved within an EU pharmaceutical me